Aquestive Adds Biopharma Veteran to Board Ahead of Potential Anaphylm Launch
Event summary
- Aquestive Therapeutics appoints Richard Daly to its Board of Directors, effective October 14, 2026.
- Daly brings over 30 years of biopharmaceutical experience, including leadership roles at AstraZeneca, Takeda, and Catalyst Pharmaceuticals.
- Board expands to eight members, seven of whom are independent under Nasdaq standards.
- Appointment comes ahead of potential FDA approval and launch of Anaphylm for severe allergic reactions.
The big picture
Aquestive's appointment of Richard Daly reflects a strategic move to bolster its commercial capabilities ahead of a potential product launch. Daly's extensive experience in launching and scaling biopharmaceutical products positions Aquestive to navigate the complexities of bringing Anaphylm to market. This board addition comes at a critical juncture for Aquestive as it prepares for a significant regulatory and commercial milestone.
What we're watching
- Commercial Readiness
- How Daly's experience will shape Aquestive's preparations for Anaphylm's potential launch.
- Regulatory Timeline
- The pace at which Anaphylm advances through FDA review and approval.
- Board Dynamics
- Whether Daly's addition will influence Aquestive's strategic direction beyond commercialization.
Related topics